Marked Weight Loss, Muscle Wasting and Fatigue on Administration of Empagliflozin in a Subject with Type 2 Diabetes
Journal of Advances in Medicine and Medical Research · pp. 1–7 · Published 9 May 2017
10.9734/BJMMR/2017/33253Abstract
Background: Weight loss, fatigue and decreased quality of life are frequently reported at the time of initial diagnosis by subjects with Diabetes Mellitus of both types although far more frequently with type 1 and are attributed to fluid and electrolyte losses due to persistent glycosuria as well as decline in adipose tissue secondary to lipolysis. However, muscle wasting and weakness as initial manifestations are noted almost exclusively in subjects with type 1 diabetes. Case Report: A man with history of type 2 diabetes about 10 years reported onset of general fatigue, polyuria, nocturia, polydipsia as well as profound progressive weight loss, muscle wasting and weakness within 2 weeks after initiation of Empagliflozin. He had been receiving glimepiride 8 mg and metformin 2000 mg daily for about 5.5 years. Resolution of polyuria, nocturia and polydipsia was attained promptly within a week after discontinuation of Empagliflozin and initiation of insulin glargine. Weight gain and improvement in fatigue began by 2 weeks, continued until achieving desirable glycemic control over next 4 months and then stabilized. However, muscle mass and strength have not yet returned to the level prior to initiation of Empagliflozin during the follow up period of 12 months. Conclusion: Empagliflozin is responsible for induction of transient weight loss as well as persistent muscle weakness and wasting in this subject.
Cited by 15
Shinta Yamamoto, Hiroki Yuge, Hiroshi Okada · Endocrine Practice · 2026
Claudia Stöllberger, Josef Finsterer, Birke Schneider · European Journal of Internal Medicine · 2025
O. V. Tsygankova, N. E. Evdokimova, S. S. Bayramova · Russian Journal of Cardiology · 2021
Frank Gao, Stephen Hall, Leon A Bach · Endocrinology, Diabetes & Metabolism Case Reports · 2020
Heidi Boutros, Chinwenwa Okeagu, Aman Sharma · Cureus · 2021
Christopher A. Gravel, Daniel Krewski, Donald R. Mattison · British Journal of Clinical Pharmacology · 2023
Panagiotis-Nikolaos Lalagkas, Georgios Poulentzas, Christos Kontogiorgis · Expert Opinion on Drug Metabolism & Toxicology · 2021
Anaghashree Udayashankar, Topoti Mukherjee, Kristin George · Indian Journal of Nephrology · 2024
Sana Khan, Ashley Broce · JCEM Case Reports · 2024
Udaya M Kabadi · Journal of Diabetes, Metabolic Disorders & Control · 2021
Related research
- Risk Factors of Hypertension among Type 2 Diabetic Patients in Imo state, South East of Nigeria — shares topic coverage
- Patient-Related Factors Affecting Type 2 Diabetes Medication Non-Adherence: A Comprehensive Review of BMI, Knowledge Levels, Treatment Concerns, and Self-Efficacy — shares topic coverage
- The Prevalence of Microalbuinuria & Associated Risk Factors at the Time of Diagnosis among Type 2 Diabetic Patients in Rajshahi City, Bangladesh — shares topic coverage
- Integrating Sglt-2 Inhibitors into the Clinical Management of Type 2 Diabetes Mellitus and Chronic Kidney Disease: Current Evidence and Future Outlook — shares topic coverage
- Comparative Effects of Psyllium and Methylcellulose on LDL Cholesterol and Glycemic Control in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
15
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.